LLY

715

-3.06%↓

JNJ

151.66

-1.63%↓

ABBV

180.76

-1.4%↓

NVO

67.55

-2.64%↓

UNH

299.78

-2.76%↓

LLY

715

-3.06%↓

JNJ

151.66

-1.63%↓

ABBV

180.76

-1.4%↓

NVO

67.55

-2.64%↓

UNH

299.78

-2.76%↓

LLY

715

-3.06%↓

JNJ

151.66

-1.63%↓

ABBV

180.76

-1.4%↓

NVO

67.55

-2.64%↓

UNH

299.78

-2.76%↓

LLY

715

-3.06%↓

JNJ

151.66

-1.63%↓

ABBV

180.76

-1.4%↓

NVO

67.55

-2.64%↓

UNH

299.78

-2.76%↓

LLY

715

-3.06%↓

JNJ

151.66

-1.63%↓

ABBV

180.76

-1.4%↓

NVO

67.55

-2.64%↓

UNH

299.78

-2.76%↓

Search

Ocular Therapeutix Inc

Avatud

SektorTervishoid

7.29 -0.82

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.1

Max

7.42

Põhinäitajad

By Trading Economics

Sissetulek

-16M

-64M

Müük

-6.4M

11M

Aktsiakasum

-0.372

Kasumimarginaal

-602.342

Töötajad

274

EBITDA

-20M

-64M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+131.05% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-128M

1.2B

Eelmine avamishind

8.11

Eelmine sulgemishind

7.29

Uudiste sentiment

By Acuity

50%

50%

187 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Ocular Therapeutix Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. mai 2025, 23:25 UTC

Kuumad aktsiad

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21. mai 2025, 21:57 UTC

Omandamised, ülevõtmised, äriostud

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21. mai 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Millicom to Acquire Telefónica's Operations in Uruguay

21. mai 2025, 21:01 UTC

Suurimad hinnamuutused turgudel

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21. mai 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21. mai 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21. mai 2025, 23:33 UTC

Omandamised, ülevõtmised, äriostud

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21. mai 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21. mai 2025, 23:32 UTC

Omandamised, ülevõtmised, äriostud

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21. mai 2025, 23:32 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21. mai 2025, 23:31 UTC

Omandamised, ülevõtmised, äriostud

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21. mai 2025, 23:30 UTC

Omandamised, ülevõtmised, äriostud

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21. mai 2025, 23:30 UTC

Omandamised, ülevõtmised, äriostud

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21. mai 2025, 23:29 UTC

Omandamised, ülevõtmised, äriostud

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21. mai 2025, 23:28 UTC

Tulu

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21. mai 2025, 23:27 UTC

Tulu

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21. mai 2025, 23:26 UTC

Tulu

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21. mai 2025, 23:26 UTC

Tulu

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21. mai 2025, 23:26 UTC

Tulu

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21. mai 2025, 23:23 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21. mai 2025, 23:22 UTC

Peamised uudised

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21. mai 2025, 23:22 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21. mai 2025, 23:20 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21. mai 2025, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21. mai 2025, 23:04 UTC

Peamised uudised

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21. mai 2025, 21:46 UTC

Peamised uudised

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21. mai 2025, 21:42 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21. mai 2025, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Millicom to Acquire Telefónica's Ops in Uruguay

21. mai 2025, 21:07 UTC

Peamised uudised

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21. mai 2025, 21:06 UTC

Omandamised, ülevõtmised, äriostud

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Ocular Therapeutix Inc Prognoos

Hinnasiht

By TipRanks

131.05% tõus

12 kuu keskmine prognoos

Keskmine 17.56 USD  131.05%

Kõrge 22 USD

Madal 14 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Ocular Therapeutix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

10

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.97 / 7.62Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

187 / 382 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.